Literature DB >> 11756185

Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.

Tatjana Stankovic1, Grant S Stewart, Christopher Fegan, Paul Biggs, James Last, Philip J Byrd, Russell D Keenan, Paul A H Moss, Alexander M R Taylor.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous disease involving more than one molecular mechanism that leads to the transformation of CD5(+) B cells at either the pregerminal or postgerminal center stage of differentiation. It was previously demonstrated that ataxia telangiectasia mutated (ATM) gene mutations can occur in B-CLL and cause a defect in the p53 pathway. Here the role of ATM mutations in the pathogenesis of B-CLL is addressed. Of 50 B-CLL tumors with fully analyzed ATM and TP53, 16 had ATM mutations. Six of 50 B-CLLs showed mutations in TP53 and the remaining 28 tumors had wild-type ATM or TP53. No tumor had both ATM and TP53 mutations. Remarkably, all 16 ATM mutant B-CLLs showed the absence of somatic variable region heavy chain hypermutation indicating a pregerminal center cell origin and a common pathogenesis for these tumors. Furthermore, in 5 of the 16 B-CLLs, ATM mutation preceded the transformation stage of differentiation. At the cellular level, ATM mutant tumors exhibited a deficient ATM-dependent p53 response to gamma irradiation, failure to up-regulate TRAIL-R2, a downstream target that links irradiation-induced p53 response with apoptosis, and an inability to repair induced chromosome breaks. Mantle cell lymphoma (MCL) is also of pregerminal center origin and ATM mutations are frequent in this malignancy. It is concluded that ATM is likely to play an important role at the pregerminal center stage and a model is proposed where loss of ATM function during B-cell ontogeny drives B-CLL tumorigenesis in pregerminal B cells by a dual defect in p53 damage response and repair of chromosome breaks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756185     DOI: 10.1182/blood.v99.1.300

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.

Authors:  Hyunjoo Lee; Shabirul Haque; Jennifer Nieto; Joshua Trott; John K Inman; Steven McCormick; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

3.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

4.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Authors:  Lesley-Ann Sutton; Viktor Ljungström; Larry Mansouri; Emma Young; Diego Cortese; Veronika Navrkalova; Jitka Malcikova; Alice F Muggen; Martin Trbusek; Panagiotis Panagiotidis; Frederic Davi; Chrysoula Belessi; Anton W Langerak; Paolo Ghia; Sarka Pospisilova; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

5.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Authors:  Gerard Lozanski; Amy S Ruppert; Nyla A Heerema; Arletta Lozanski; David M Lucas; Amber Gordon; John G Gribben; Vicki A Morrison; Kanti M Rai; Guido Marcucci; Richard A Larson; John C Byrd
Journal:  Leuk Lymphoma       Date:  2012-06-02

Review 6.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

7.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

8.  Development of a biomarker database toward performing disease classification and finding disease interrelations.

Authors:  Shaikh Farhad Hossain; Ming Huang; Naoaki Ono; Aki Morita; Shigehiko Kanaya; Md Altaf-Ul-Amin
Journal:  Database (Oxford)       Date:  2021-03-11       Impact factor: 3.451

9.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

10.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.